D.E. Shaw & Co
MRNA icon

D.E. Shaw & Co’s Moderna MRNA Stock Holding History

D.E. Shaw & Co’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$33.9M Sell
666,532
-4,516,227
-87% -$211M 0.02% 854
2025
Q4 		$153M Sell
5,182,759
-963,615
-16% -$26.2M 0.08% 271
2025
Q3 		$159M Sell
6,146,374
-1,317,181
-18% -$36.7M 0.09% 247
2025
Q2 		$206M Buy
7,463,555
+1,827,404
+32% +$48.1M 0.15% 144
2025
Q1 		$160M Buy
5,636,151
+3,867,436
+219% +$137M 0.14% 163
2024
Q4 		$73.5M Buy
1,768,715
+1,509,591
+583% +$72.2M 0.05% 426
2024
Q3 		$17.3M Buy
+259,124
New +$23.8M 0.01% 1087
2024
Q2 		– Sell
-48,022
Closed -$6.08M – 4708
2024
Q1 		$5.12M Sell
48,022
-314,155
-87% -$31.7M ﹤0.01% 1869
2023
Q4 		$36M Buy
362,177
+303,845
+521% +$25.6M 0.03% 605
2023
Q3 		$6.03M Sell
58,332
-20,175
-26% -$2.25M 0.01% 1662
2023
Q2 		$9.54M Sell
78,507
-189,573
-71% -$25.3M 0.01% 1377
2023
Q1 		$41.2M Sell
268,080
-298,928
-53% -$49.3M 0.04% 508
2022
Q4 		$102M Buy
567,008
+294,842
+108% +$48.2M 0.11% 198
2022
Q3 		$32.2M Buy
272,166
+245,352
+915% +$37.2M 0.04% 597
2022
Q2 		$3.83M Sell
26,814
-1,227,130
-98% -$175M ﹤0.01% 2459
2022
Q1 		$216M Buy
1,253,944
+240,949
+24% +$40.6M 0.2% 78
2021
Q4 		$257M Buy
1,012,995
+259,232
+34% +$75.8M 0.21% 72
2021
Q3 		$290M Sell
753,763
-920,545
-55% -$340M 0.26% 51
2021
Q2 		$393M Buy
1,674,308
+1,616,152
+2,779% +$289M 0.34% 40
2021
Q1 		$7.62M Sell
58,156
-3,051,745
-98% -$442M 0.01% 1550
2020
Q4 		$325M Buy
3,109,901
+2,343,772
+306% +$237M 0.29% 50
2020
Q3 		$54.2M Buy
766,129
+455,804
+147% +$31.8M 0.06% 387
2020
Q2 		$19.9M Buy
310,325
+262,490
+549% +$14.4M 0.02% 780
2020
Q1 		$1.43M Sell
47,835
-327,503
-87% -$7.53M ﹤0.01% 2445
2019
Q4 		$7.34M Buy
+375,338
New +$6.66M 0.01% 1431
2019
Q3 		– Sell
-25,128
Closed -$368K – 3940
2019
Q2 		$368K Buy
+25,128
New +$540K ﹤0.01% 3222

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

D.E. Shaw & Co's MRNA Position: Q1 2026 in Review

D.E. Shaw & Co reduced its Moderna (MRNA) stake by 87% in Q1 2026, selling an estimated $211M and leaving 666,532 shares worth $33.9M. The position accounts for 0.02% of the portfolio, ranked #854.

D.E. Shaw & Co first reported a position in MRNA in Q2 2019 and has held it in 26 quarters since. The position peaked at $393M in Q2 2021. 722 funds tracked by Wall St. Rank hold MRNA as of Q1 2026.

  • D.E. Shaw & Co held 666,532 shares of Moderna worth $33.9M as of Q1 2026.
  • D.E. Shaw & Co sold 4,516,227 Moderna shares in Q1 2026, an estimated $211M.
  • Moderna made up 0.02% of D.E. Shaw & Co's portfolio in Q1 2026, its #854 holding.
  • D.E. Shaw & Co first reported a position in Moderna in Q2 2019 and has held it in 26 quarters since.
  • D.E. Shaw & Co's Moderna position peaked at $393M in Q2 2021.
  • 722 funds tracked by Wall St. Rank held Moderna as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.